Kiora Pharmaceuticals: Strong Buy Rating on Strategic Partnership and Promising Trial Results
Kiora Pharmaceuticals Analyst Ratings
Kiora Pharmaceuticals (KPRX) Receives a Buy From Maxim Group
Analysts Offer Insights on Healthcare Companies: Syros Pharmaceuticals (SYRS) and Kiora Pharmaceuticals (KPRX)
HC Wainwright & Co. Reiterates Buy on Kiora Pharmaceuticals, Maintains $3.5 Price Target
Kiora Pharmaceuticals Analyst Ratings
Promising Clinical Trials and Innovative Trajectory Bolsters Buy Rating for Kiora Pharmaceuticals
Analysts Offer Insights on Healthcare Companies: Cassava Sciences (SAVA), Kiora Pharmaceuticals (KPRX) and Bluebird Bio (BLUE)
HC Wainwright & Co. Maintains Buy on Kiora Pharmaceuticals, Raises Price Target to $3.5
Kiora Pharmaceuticals Analyst Ratings
Kiora Pharmaceuticals (KPRX) Receives a Buy From Maxim Group
HC Wainwright & Co. Reiterates Buy on Kiora Pharmaceuticals, Maintains $2 Price Target
Kiora Pharmaceuticals Analyst Ratings
H.C. Wainwright Sticks to Their Buy Rating for Kiora Pharmaceuticals (KPRX)
HC Wainwright & Co. Maintains Buy on Kiora Pharmaceuticals, Lowers Price Target to $2
Kiora Pharmaceuticals Analyst Ratings
HC Wainwright Raises Kiora Pharmaceuticals' Price Target to $7 From $6, Maintains Buy Rating
Maxim Group Sticks to Their Buy Rating for Kiora Pharmaceuticals (KPRX)
H.C. Wainwright Remains a Buy on Kiora Pharmaceuticals (KPRX)
Analyst Ratings for Kiora Pharmaceuticals
No Data